TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

TESTOPEL

TESTOSTERONE Androgen Receptor Agonists
Oncology Approved 1972-07-13
1
Indication
--
Phase 3 Trials
53
Years on Market

Details

Status
Prescription
First Approved
1972-07-13
Routes
IMPLANTATION
Dosage Forms
PELLET

Companies

Active Ingredient: TESTOSTERONE

TESTOPEL Approval History

Loading approval history...

What TESTOPEL Treats

2 indications

TESTOPEL is approved for 2 conditions since its original approval in 1972. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypogonadism
  • Delayed Puberty
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TESTOPEL FDA Label Details

Pro

Indications & Usage

MALES Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of s...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.